532 related articles for article (PubMed ID: 16835968)
1. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.
Hussein MA; Baz R; Srkalovic G; Agrawal N; Suppiah R; Hsi E; Andresen S; Karam MA; Reed J; Faiman B; Kelly M; Walker E
Mayo Clin Proc; 2006 Jul; 81(7):889-95. PubMed ID: 16835968
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
[TBL] [Abstract][Full Text] [Related]
3. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial.
Rifkin RM; Gregory SA; Mohrbacher A; Hussein MA
Cancer; 2006 Feb; 106(4):848-58. PubMed ID: 16404741
[TBL] [Abstract][Full Text] [Related]
4. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
Waterman GN; Yellin O; Swift RA; Mapes R; Eades B; Ackerman E; Berenson JR
Ann Hematol; 2011 Feb; 90(2):193-200. PubMed ID: 20809423
[TBL] [Abstract][Full Text] [Related]
5. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma.
Baz R; Li L; Kottke-Marchant K; Srkalovic G; McGowan B; Yiannaki E; Karam MA; Faiman B; Jawde RA; Andresen S; Zeldis J; Hussein MA
Mayo Clin Proc; 2005 Dec; 80(12):1568-74. PubMed ID: 16342649
[TBL] [Abstract][Full Text] [Related]
6. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P
Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].
Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
Ai Zheng; 2007 Dec; 26(12):1369-72. PubMed ID: 18076804
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.
Berenson JR; Yellin O; Kazamel T; Hilger JD; Chen CS; Cartmell A; Woliver T; Flam M; Bravin E; Nassir Y; Vescio R; Swift RA
Leukemia; 2012 Jul; 26(7):1675-80. PubMed ID: 22354206
[TBL] [Abstract][Full Text] [Related]
10. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study.
Offidani M; Corvatta L; Marconi M; Visani G; Alesiani F; Brunori M; Galieni P; Catarini M; Burattini M; Centurioni R; Rupoli S; Scortechini AR; Giuliodori L; Candela M; Capelli D; Montanari M; Olivieri A; Piersantelli MN; Leoni P
Haematologica; 2006 Jan; 91(1):133-6. PubMed ID: 16434383
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
[TBL] [Abstract][Full Text] [Related]
12. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study.
Offidani M; Corvatta L; Polloni C; Piersantelli MN; Gentili S; Galieni P; Visani G; Alesiani F; Catarini M; Brunori M; Samori A; Burattini M; Centurioni R; Ferranti M; Giuliodori L; Candela M; Mele A; Marconi M; Leoni P
Br J Haematol; 2009 Mar; 144(5):653-9. PubMed ID: 19036082
[TBL] [Abstract][Full Text] [Related]
15. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
16. [Thalidomide with or without dexamethasone for refractory multiple myeloma].
Boulin M; Blanchet F; Isambert N; Solary E; Solier S; Collin B; Pernot C; Durnet-Archeray MJ
Therapie; 2002; 57(6):524-9. PubMed ID: 12666259
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
[TBL] [Abstract][Full Text] [Related]
18. Modifications to therapy for multiple myeloma: pegylated liposomal Doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide.
Hussein MA
Oncologist; 2003; 8 Suppl 3():39-45. PubMed ID: 14671227
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy.
Baz R; Walker E; Karam MA; Choueiri TK; Jawde RA; Bruening K; Reed J; Faiman B; Ellis Y; Brand C; Srkalovic G; Andresen S; Knight R; Zeldis J; Hussein MA
Ann Oncol; 2006 Dec; 17(12):1766-71. PubMed ID: 16980599
[TBL] [Abstract][Full Text] [Related]
20. Clinical benefits and economic analysis of pegylated liposomal doxorubicin/vincristine/dexamethasone versus doxorubicin/vincristine/dexamethasone in patients with newly diagnosed multiple myeloma.
Porter CA; Rifkin RM
Clin Lymphoma Myeloma; 2007 Apr; 7 Suppl 4():S150-5. PubMed ID: 17562253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]